Skip to main content
Clinical Trials/NCT04636853
NCT04636853
Completed
Phase 3

Cord Blood Platelet-rich Plasma (CB-PRP) in Retinitis Pigmentosa and Dry Age-related Macular Degeneration

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1 site in 1 country20 target enrollmentDecember 23, 2020

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Retinitis Pigmentosa
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
20
Locations
1
Primary Endpoint
Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) morphological changes
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The study will provides the enrollment of patients with genetic retinal dystrophies with primary rod impairment and dry age-related macular degeneration (Geographic type) A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.

A complete morpho-functional ophthalmological evaluation will be performed in all patients at each control.

Detailed Description

All patients underwent genetic evaluation and they reported different types of mutations that induce anatomic-functional impairment of the rods. Patients affected by bilateral dry age-related macular degeneration (Geographic type) will be recruited as well. After selecting the patients to be enrolled, the study will proceed with the vitrectomy surgery and subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) provided by the Umbilical Cord Bank according to the procedures provided for by the current legislation on blood components for non-transfusion use. A complete ophthalmological examination will be performed at 1, 3, 6, and 12 months. They will include: * Anterior segment biomicroscopy * direct and indirect ophthalmoscopy * ETDRS visual acuity assessment * intraocular pressure measurement * optical coherence tomography (OCT) * OCT Angiography (OCTA) The following assessments will be performed at baseline and at 6 and 12 months. * Microperimetry * Electroretinogram (ERG) * Visually evoked potential (VEP) * contrast sensitivity (MARS tables) * Goldmann perimetry Some morpho-functional data will also be collected in the contralateral eye and used as the control group. To ensure the best safety for the patient, the first 5 eyes will be separated by a minimum of 20 days in order to observe the post-surgical evolution.

Registry
clinicaltrials.gov
Start Date
December 23, 2020
End Date
December 2, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Retinal dystrophies with compromised rods (only for RP patients)
  • Visual Field (Manual Goldmann) V / 4e \< 30 ° (only for RP patients)
  • Best corrected visual acuity \> Light perception
  • Known genotype
  • No or minimal opacity of ocular media
  • No concomitant ocular (eg glaucoma, amblyopia)
  • Dry Age-related Macular Degeneration (Geographic type)

Exclusion Criteria

  • Age\<18 years
  • Pregnancy
  • Previous inflammatory / infectious events involving the eyes

Outcomes

Primary Outcomes

Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) morphological changes

Time Frame: 3 years

Differences in structural optical coherence tomography (OCT) and OCT Angiography (OCTA) images

Study Sites (1)

Loading locations...

Similar Trials